TargetMol

RG2833

Product Code:
 
TAR-T6639
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6639-5mg5mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6639-1mL1 mL * 10 mM (in DMSO)£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6639-10mg10mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6639-25mg25mg£153.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6639-50mg50mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6639-100mg100mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6639-200mg200mg£336.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6639-500mg500mg£519.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
RG2833 (RGFP109), a brain-penetrant HDAC inhibitor, is with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.
CAS:
1215493-56-3
Formula:
C20H25N3O2
Molecular Weight:
339.439
Pathway:
DNA Damage/DNA Repair; Chromatin/Epigenetic
Purity:
0.9913
SMILES:
Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N
Target:
HDAC

References

Sandi C, et al. Neurobiol Dis. 2011, 42(3), 496-505. Johnston TH, et al. Parkinsonism Relat Disord. 2013, 19(2), 260-264. Rai M, et al. PLoS One. 2010, 5(1), e8825.